vs
百利高（PRGO）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是百利高的1.9倍（$2.1B vs $1.1B），Roper Technologies净利率更高（15.8% vs -127.8%，领先143.6%），Roper Technologies同比增速更快（11.3% vs -2.5%），Roper Technologies自由现金流更多（$507.0M vs $148.6M），过去两年Roper Technologies的营收复合增速更高（10.5% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
PRGO vs ROP — 直观对比
营收规模更大
ROP
是对方的1.9倍
$1.1B
营收增速更快
ROP
高出13.8%
-2.5%
净利率更高
ROP
高出143.6%
-127.8%
自由现金流更多
ROP
多$358.4M
$148.6M
两年增速更快
ROP
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $2.1B |
| 净利润 | $-1.4B | $331.0M |
| 毛利率 | 32.6% | 69.4% |
| 营业利润率 | -116.0% | 27.2% |
| 净利率 | -127.8% | 15.8% |
| 营收同比 | -2.5% | 11.3% |
| 净利润同比 | -3093.9% | 53.7% |
| 每股收益（稀释后） | $-10.23 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGOROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.0B | $2.0B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $1.1B | $1.8B | ||
| Q2 24 | $1.1B | $1.7B |
净利润PRGOROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $-1.4B | $428.4M | ||
| Q3 25 | $7.5M | $398.5M | ||
| Q2 25 | $-8.4M | $378.3M | ||
| Q1 25 | $-6.4M | $331.1M | ||
| Q4 24 | $-44.4M | $462.3M | ||
| Q3 24 | $-21.0M | $367.9M | ||
| Q2 24 | $-108.4M | $337.1M |
毛利率PRGOROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 32.6% | 69.5% | ||
| Q3 25 | 36.1% | 69.5% | ||
| Q2 25 | 34.4% | 69.2% | ||
| Q1 25 | 37.6% | 68.7% | ||
| Q4 24 | 33.9% | 68.3% | ||
| Q3 24 | 37.2% | 69.2% | ||
| Q2 24 | 37.0% | 69.5% |
营业利润率PRGOROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | -116.0% | 28.6% | ||
| Q3 25 | 7.0% | 28.4% | ||
| Q2 25 | 4.3% | 28.2% | ||
| Q1 25 | 4.5% | 27.9% | ||
| Q4 24 | 10.0% | 28.0% | ||
| Q3 24 | 7.4% | 28.1% | ||
| Q2 24 | -2.5% | 28.8% |
净利率PRGOROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | -127.8% | 20.8% | ||
| Q3 25 | 0.7% | 19.8% | ||
| Q2 25 | -0.8% | 19.5% | ||
| Q1 25 | -0.6% | 17.6% | ||
| Q4 24 | -3.9% | 24.6% | ||
| Q3 24 | -1.9% | 20.8% | ||
| Q2 24 | -10.2% | 19.6% |
每股收益（稀释后）PRGOROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $-10.23 | $3.97 | ||
| Q3 25 | $0.05 | $3.68 | ||
| Q2 25 | $-0.06 | $3.49 | ||
| Q1 25 | $-0.05 | $3.06 | ||
| Q4 24 | $-0.32 | $4.29 | ||
| Q3 24 | $-0.15 | $3.40 | ||
| Q2 24 | $-0.79 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $382.9M |
| 总债务越低越好 | — | $9.7B |
| 股东权益账面价值 | $2.9B | $18.8B |
| 总资产 | $8.5B | $34.6B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资PRGOROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | — | $297.4M | ||
| Q3 25 | $432.1M | $320.0M | ||
| Q2 25 | $454.2M | $242.4M | ||
| Q1 25 | $409.9M | $372.8M | ||
| Q4 24 | $558.8M | $188.2M | ||
| Q3 24 | $1.5B | $269.6M | ||
| Q2 24 | $542.8M | $251.5M |
总债务PRGOROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | — | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PRGOROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $2.9B | $19.9B | ||
| Q3 25 | $4.4B | $20.0B | ||
| Q2 25 | $4.5B | $19.6B | ||
| Q1 25 | $4.4B | $19.2B | ||
| Q4 24 | $4.3B | $18.9B | ||
| Q3 24 | $4.6B | $18.5B | ||
| Q2 24 | $4.5B | $18.1B |
总资产PRGOROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $8.5B | $34.6B | ||
| Q3 25 | $10.1B | $34.6B | ||
| Q2 25 | $10.1B | $33.2B | ||
| Q1 25 | $9.8B | $31.4B | ||
| Q4 24 | $9.6B | $31.3B | ||
| Q3 24 | $11.2B | $31.6B | ||
| Q2 24 | $10.4B | $29.8B |
负债/权益比PRGOROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | — |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $507.0M |
| 自由现金流率自由现金流/营收 | 13.4% | 24.2% |
| 资本支出强度资本支出/营收 | 2.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | — |
8季度趋势，按日历期对齐
经营现金流PRGOROP
| Q1 26 | — | — | ||
| Q4 25 | $175.4M | $738.0M | ||
| Q3 25 | $51.7M | $869.5M | ||
| Q2 25 | $75.9M | $404.1M | ||
| Q1 25 | $-64.5M | $528.7M | ||
| Q4 24 | $312.6M | $722.2M | ||
| Q3 24 | $42.2M | $755.4M | ||
| Q2 24 | $9.5M | $384.1M |
自由现金流PRGOROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $148.6M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $56.7M | — | ||
| Q1 25 | $-90.0M | — | ||
| Q4 24 | $274.9M | — | ||
| Q3 24 | $15.1M | — | ||
| Q2 24 | $-18.9M | — |
自由现金流率PRGOROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 13.4% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 5.4% | — | ||
| Q1 25 | -8.6% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | -1.8% | — |
资本支出强度PRGOROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 2.7% | — |
现金转化率PRGOROP
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | 6.89× | 2.18× | ||
| Q2 25 | — | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
ROP
暂无分部数据
